ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 717

Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study

Alicia Hinze1, Philip Chu1, Dany Thekkemuriyil1, Yo-El Ju2, Deepali Sen3, Seth Eisen1 and Alfred Kim1, 1Rheumatology, Washington University School of Medicine, Saint Louis, MO, 2Neurology, Washington University School of Medicine, Saint Louis, MO, 3Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: quality of life, sleep and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sleep disturbances occur in many autoimmune diseases and are
ranked highly as an unmet need in patients with SLE. We hypothesized that poor
sleep increased SLE disease activity and decreased quality of life (QoL). The aims of this pilot study was to describe in SLE
patients: 1) the prevalence of sleep problems, 2) evaluate the impact of sleep
problems on quality of life (QoL), and 3) compare
sleep problems with disease activity.

Methods: 27 patients with a confirmed diagnosis of SLE according
to the 1997 ACR classification criteria for SLE or the SLICC classification criteria
for SLE were enrolled in this cross-sectional study. Comorbid conditions were
identified by patient’s clinic intake assessment and review of electronic
medical records. Patients completed three sleep surveys at the enrollment
visit: Pittsburgh Sleep Quality Index (PSQI), Patient Reported Outcomes
Measurement Instrument System (PROMIS) short form for Sleep Disturbance, and
PROMIS short form for Sleep Related Impairment. Disease activity assessed using
SLEDAI2K Responder Index-50 (S2K RI-50). Lupus Impact Tracker (LIT) evaluated
patient reported QoL. Student’s t-test compared means
from independent samples, ANOVA compared categorical variables with normally distributed
continuous variables, and Kruskal Wallis compared
categorical variables with non-normally distributed continuous variables.

Results: 1) Prevalence of sleep problems in patients with SLE was 85%
as defined by PQSI score > 5 (Table 1). SLE patients experience greater
sleep disturbance and sleep impairment as measured by the PROMIS surveys when
compared to the general population. 2) SLE QoL was significantly
higher in patients with good sleep. 3) Increased S2K RI-50 scores were observed
in patients with poor sleep, though results did not reach statistical
significance.

Conclusion: There is a higher prevalence of poor sleep quality among
patients with SLE and this was shown to strongly associated with patient
reported QoL. Higher SLE disease activity was seen in
patients with poor sleep, though directionality of this association is unable
to be determined in this small, cross-sectional study. Longitudinal studies with
actigraphy are currently underway to further examine
this relationship.

Table 1


Disclosure: A. Hinze, None; P. Chu, None; D. Thekkemuriyil, None; Y. E. Ju, None; D. Sen, None; S. Eisen, None; A. Kim, Kypha, Inc., 2,Amgen, Janssen, Pfizer, 5.

To cite this abstract in AMA style:

Hinze A, Chu P, Thekkemuriyil D, Ju YE, Sen D, Eisen S, Kim A. Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-and-the-evaluation-of-poor-sleep-the-sleeps-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-and-the-evaluation-of-poor-sleep-the-sleeps-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology